Immunotherapeutic agents have been researched for many decades as an alternative treatment for cancer. Current research demonstrates that immunotherapy is safer than radiotherapy or chemotherapy. This is attributed to immunotherapy’s mechanism of utilizing the body’s own defense system, as opposed to absorbing harmful chemicals. Two forms of immunotherapy that have been effective in curing cancer without the added danger of chemical toxicity are PNC-27 and PNC-28. These peptides were created by a supercomputer at SUNY Downstate Medical Center in New York in 2000. PNC-27 and PNC-28 work with the MDM2 -P53 tumor suppressor complex. It acts as a competitive inhibitor for binding, increasing the half-life of P53 in the cell and assisting with the elimination of cancer cells (Sarafraz-Yazdi E, Bowne WB, et al 2010). These immunotherapy agents also have the ability to bind to the cell membrane and lyse the cell. The clinical trials for PNC-27 and 28 were successful, and the drug is currently in use outside of the United States. Although this form of immunotherapy does come with some side effects, research illustrates that this form of immunotherapy can be a successful strategy in eliminating the cancer and ensuring that a relapse does not occur.
Silberstein, M. (2020). Is PNC-27 and PNC-28 the Best way to cure Cancer?. The Science Journal of the Lander College of Arts and Sciences, 13(2). Retrieved from https://touroscholar.touro.edu/sjlcas/vol13/iss2/7